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Abstract: Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clin-
ical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are the leading 
reasons. Reducing attrition rate can be achieved by various means, starting with a comprehensive evaluation of the po-
tential safety issues associated to the primary target followed by an evaluation of undesirable secondary targets. To ad-
dress these risks, a risk mitigation plan should be built at very early development stages, using a panel of in silico, in 
vitro, and in vivo models. While most pharmaceutical companies have developed robust safety strategies to de-risk 
genotoxicity and cardiotoxicity issues, partly driven by regulatory requirements; safety issues affecting other organs or 
systems, such as the central nervous system, liver, kidney, or gastro-intestinal system are less commonly addressed 
during early drug development. This paper proposes some de-risking strategies that can be applied to these target organ 
systems, including the use of novel biomarkers that can be easily integrated in both preclinical and clinical studies. Ex-
periments to understand the mechanisms’ underlying toxicity are also important. Two examples are provided to demon-
strate how such mechanistic studies can impact drug development. Novel trends in investigative safety are reviewed, such 
as computational modeling, mitochondrial toxicity assessment, and imaging technologies. Ultimately, understanding the 
predictive value of non-clinical safety testing and its translatability to humans will enable to optimize assays in order to 
address the key objectives of the drug discovery process, i.e., hazard identification, risk assessment, and mitigation. 
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1. Introduction: Understanding the Attrition 
Challenge in Drug Development 
espite major breakthroughs for some diseases 
in recent decades, many of the most common 
human diseases are not effectively treated by  
existing therapies. Drug development is a science-dri-
ven, research-intensive, long lasting, and high-risk end-
eavor[1]. It is well-established that R&D productivity 
is a particularly difficult challenge to overcome in the 
pharmaceutical sector[2]. The cost of inventing new 
drugs has greatly increased since 1970, whereas the 
overall output of investigational new drug products  
has remained relatively constant whilst return on in-
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vestment is going down[1–3]. Attrition rates of clinical 
stages have risen sharply in the last decade, especially 
in late-phase clinical trials. Thus, understanding the 
root causes of why compounds undergo attrition, and 
reducing these rates are crucial to better understand 
pharmaceutical industry performance and improve 
drug development efficiency[4–6]. Only 15% of the 
molecules that enter clinical trials receive marketing 
approval, and drug success rates differ across different 
stages of development[7,8]. It has been reported that 
around 30%–50% of the projects that are in phase 3 
clinical trials fail to be launched on the market[9]. Ac-
cording to recent reports, Phase II, with an attrition 
rate higher than 50%, has the highest attrition fre-
quency in the drug development process[10,11]. Many 
factors contribute to attrition, and drug development 
success rates vary dramatically between different the-
rapeutic areas[12]. A survey revealed that molecules 
undergoing attrition during the preclinical stage are 
withdrawn from further clinical development for var-
ious causes, such as lack of efficacy and safety issues, 
poor absorption, distribution, metabolism and elimi-
nation (ADME) properties, market competition, and 
commercial interests[9,12].  
More specifically, over the last two decades, both 
preclinical and clinical safety have remained the major 
cause of drug attrition during clinical development and 
of drug withdrawal from the market, accounting for 
35%–40% of all drug discontinuation[13,14]. Although 
the safety related reasons for attrition have evolved 
over the years, cardiac and hepatic toxicities have re-
mained the leading reasons for attrition[15,16] fol-
lowed by, to a much lower extent, neurological, renal, 
and gastro-intestinal related toxicities. It must be 
stressed that target organ toxicities can be functional 
and/or structural in nature. Furthermore, the relative 
contribution to adverse drug reactions, attrition, with-
drawal, and labeling implications vary from one type 
of toxicity to another and from one organ system to 
the other[13].   
Numerous solutions have been proposed, but the 
mindset of reducing attrition in development should be 
in place from the earliest stages of discovery. Some 
approaches include, but are not limited to, improving 
pre-clinical testing (efficacy, safety, ADME)[11], de-
signing proof-of-concept clinical trials[12], formulation 
and drug delivery technologies, use of appropriate ph-
armacokinetic/pharmacodynamic (PK/PD) models[9], 
and identifying predictive biomarkers[17]. The current 
approaches to reducing safety related attrition in drug 
development are presented and discussed in this re-
view article. 
2. How to Reduce Attrition Rate  
2.1 Target Related Safety Issues 
Besides the well implemented in vitro and in vivo sa-
fety testing of promising compounds during the drug 
development process, an upfront in cerebro evaluation 
of the target can be beneficial to anticipate important 
potential safety risks at an y stages of drug develop-
ment. Indeed, for the last years, the proportion of tar-
get-related safety closures rose substantially in the 
clinical phases and this was responsible for almost 
half of the safety-related project closures[6]. Unin-
tended adverse effects can arise as a co nsequence of 
the intended primary pharmacology in organs other 
than those related to the indication or can arise from 
exaggerated secondary pharmacology[18]. To anticipate 
potential safety liabilities directly or indirectly linked 
to the target, Target Safety Evaluation (TSE) is be-
coming a s tandard practice within pharmaceutical 
companies. This TSE provides an in-depth review of 
the target and may include different sections covering 
the biology (gene, protein, function, pathway, expres-
sion profile, tissue distribution, disease,HWF), human 
genetic phenotype, transgenic animal genotype and 
phenotype (knock-out [KO], mutants), potential safety 
risks and its associated mitigation plans as well as 
competitive intelligence and differentiation criteria. It 
is a k ey step in trying to understand the safety risks 
associated with the target and helps to determine up-
front which endpoints could be measured to mitigate 
the safety risks identified. In the case that too many 
safety risks are identified compared to the poten-
tial benefit, the decision can be taken not to pursue the 
target for a particular indication. In less severe cases, 
this TSE may guide in part the development of the 
compound based on the identified liabilities. Exam-
ples of key questions that need to be addressed within 
such an evaluation are: what is known about the target 
or a close structurally related target? Are there any 
known safety implications related to the targeted path-
ways? How is the target regulated with respect to 
agonists and/or antagonists? Are there any known on- 
target and/or off-target toxicities? What information 
can be extracted from existing KO animals or models 
overexpressing the target? There are however some 
challenges to take into account with KO data. Firstly, 
some gene deletions are embryo-lethal. Secondly, the 
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observed phenotypes may be due to developmental 
effects and not to the acute effects of the absence of 
the target[19]. Finally, adaptive changes during devel-
opment can provide a “workaround” to circumvent the 
missing gene. One way round these problems is to use 
conditional KO. Of added value as well is a descrip-
tion of the information that is available regarding 
competitor activities in relation to the safety of the 
particular target or the therapeutic indication. 
Potential safety biomarkers should also be identi-
fied and deployed for use in the preclinical studies 
(e.g., blood markers and/or tissue gene expression pro-
files) together with the identification of the most rele-
vant preclinical species. Based on all the acquired 
safety information, if necessary; dedicated experi-
ments or specific endpoints within the in vivo studies 
can be put in place in order to evaluate the identified 
target-related safety issues. If available, tool com-
pounds are extremely useful in these experiments be-
cause they can help in the interpretation of severity of 
the safety risks identified. The TSE assessment is built 
through information mining and analysis of public and 
internal databases and through consultations with ex-
perts in the target specific field. During the lifespan of 
the project the TSE document needs to be updated 
regularly using the latest available literature informa-
tion as well as in the meantime generated in silico, in 
vitro, and in vivo data. If necessary the project can be 
redirected based on this newly available safety infor-
mation. 
2.2 Off Target Related Safety Issues 
Besides the (desired or unwanted) effects related to 
the action of a drug on the primary therapeutic target, 
interactions with targets other than the primary target 
can also lead to undesirable secondary effects, also 
named “off-target” effects[20]. It has been shown that 
compounds with a target hit rate (i.e., percentage of a 
panel of at least 50 targets for which more than 
50% binding is noted at 10µM) of 20% or more have a 
higher attrition rate[21]. Hopefully, off-target effects 
can be easily predicted from the in vitro pharmaco-
logical profiling that is conducted at early stages of 
discovery projects. Such profiling includes screening 
of compounds against a variety of receptors, ion cha-
nnels, enzymes, and transporters that are known to be 
associated with safety issues in humans.  
Except for the human ether-a-go-go-related gene 
(hERG) channel associated with QT prolongation and 
delayed ventricular repolarization, which is covered by 
the International Conference on Harmonization (ICH) 
S7B guidance, there is no mandatory regulatory re-
quirement on the list of targets that must be scr-
eened before moving a drug into the clinic[22]. Never-
theless, receptor binding profiling is mentioned, but 
not required, in the ICH S7A[23] and drug abuse guid-
ance[24]. However, some off-target effects may lead to 
specific regulatory actions, based on their potential 
risk for human safety[25]. Bowes et al.[21] published a 
list of 44 recommended targets that provides an early 
assessment of the potential hazard of a compound or a 
chemical series. For secondary pharmacology profil-
ing, some pharmaceutical companies apply a step-wise 
approach including at very early stage (e.g., lead op-
timization phase) a minimal panel of 10 to 20 targets 
followed by one or two successive panels with ex-
tended list of targets (50 to 150), used for deeper cha-
racterization of lead or candidate drugs. The early 
profiling will identify liabilities associated with a 
chemical series and improve compound design, while 
the expanded profiling will provide a comprehensive 
understanding of the potential side effects expected in 
preclinical studies. Measurement of direct binding 
affinity of the drug for these targets should be fol-
lowed by the assessment of its functional response on 
the hit targets (agonism, antagonism, inhibition,HWF) in 
a cell or tissue assay. Table 1 provides a list of targets 
that are associated with toxicity issues (due to off-tar-
gets effects). For example, binding of a compound to 
5-hydroxytryptamine receptor 2B (5HT2B) is not an is-
sue if it e xhibits antagonistic activity, while it sho-
uld be avoided in case of agonistic activity, due to the 
risk of cardiac valvulopathy[26]. Determination of the 
potency of the compound, expressed as EC50 or IC50 
(half maximal efficacy and inhibitory concentrations, 
respectively), is also necessary to evaluate its selectiv-
ity (ratio between EC50 or IC50 values for primary and 
secondary targets). As a general rule, a 100-fold selec-
tivity ratio is recommended to provide a s ufficient 
safety margin[27] although lower safety margins can be 
considered for instance when targeting kinases[28].  
In silico tools have been developed over the last 
decade to facilitate the interpretation and maximize 
the impact of pharmacological profiling data. Proprie-
tary databases such as Bioprint™ or DrugMatrix™ 
provide access to large datasets which can include 
chemical structures of reference and marketed drugs, 
in vitro pharmacological profiling data (binding and/or 
functional) and ADRs observed in clinical trials. These 
tools can be used to compare a new drug structure to  
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Table 1. Examples of off-target related toxicities. Adapted from Bowes et al.[20,21] and Valentin et al.[13]. 5-HT: 5-hydroxytryptamine, 
CNS: central nervous system, hERG : human ether-a-go-go related gene, TdP: Torsades de Pointes. 
Target involved Organ system affected Mechanism of action Known functional effects Known structural effects 
hERG channel Cardiovascular Ion channel  
inhibition 
Prolonged QT, TdP Embryonic malformations and 
death due to reduced cardiac 
output and hypoxia 
5-HT2B receptor Cardiovascular Agonism Pulmonary hypertension Cardiac valvulopathy 
Adrenergicbeta2 
receptor 
Cardiovascular Agonism Antagonism Tachycardia, hypotension 
Bronchospasm 
Vascular smooth muscle necro-
sis, cardiac lesions (dog) 
Dopamine transporter CNS, reproductive 
system, skin 
Inhibition Effects on c ognition and lo-
comotor activity, drug abuse 
potential, depression 
Rat specific uterine tumors, 
Acne 
Tyrosine kinases Various (cardiovascu-
lar, thyroid, blood,…) 
Inhibition Anemia, thrombopenia, hypo-
thyroidism, hypertension,… 
Congestive heart failure 
Cyclooxygenase 1 Upper gastrointestinal 
tract 
Inhibition Increased acid secretion, de-
creased mucus production 
Gastric bleeding, ulcers 
 
structures of already profiled drugs, predict phar-
macological activity on targets associated with safety 
issues, or help in the interpretation and understanding 
of side effects observed in in vivo studies[20].  
2.3 Addressing Chemistry Related Safety Issues 
2.3.1 Genotoxicity Safety Strategy 
Genotoxicity remains an important reason for drug 
attrition during pre-clinical testing and represents 
about 10% of the safety-related failures[6]. Over recent 
years, companies have therefore focused on develop-
ing testing strategies to maximize genotoxic hazard 
identification at early stages of drug development (e.g., 
lead optimization). This approach will guide the selec-
tion and ranking of pharmaceutical development can-
didates and is crucial to improve the success rate of 
newly developed drugs. In this perspective, the regu-
latory test battery, aiming at detecting DNA damage, 
can be complemented with a significant number of in 
vitro screening tools of higher throughput and higher 
speed, low compound requirement and lower cost, 
making them better adapted for incorporation in early 
phases of drug development. Since these newly avail-
able assays, developed as alternative to established 
regulatory assays, generally show a good sensitivity 
and a high specificity, they provide a comprehensive 
initial assessment of the genotoxic potential of a mo-
lecule. As no single test is capable of detecting all ge-
notoxic mechanisms which could ultimately lead to 
cancer, a battery of in vitro genotoxicity screening ass-
ays with different endpoints is considered to be the 
most reasonable approach to identify genotoxic hazard 
early on. However, today, no c onsensus on t he best 
combination of genotoxicity screening assays to use 
has been reached. Nevertheless, most companies in-
itially screen for bacterial mutagenicity using modifi-
cations of the regulatory Ames assay. Nowadays, a 
variety of assays is available each with their strengths 
and weaknesses[29]. Figure 1 gives an example of the 
strategies deployed by Lundbeck (Figure 1A) and 
UCB (Figure 1B) to triage compounds in different 
fields including genotoxicity. Some use the tradition-
al bacterial strains in miniaturized agar or liquid for-
mat (e.g., mini-Ames, micro-Ames, Ames Multi Plate 
Format [MPF]); others use modified strains (e.g., 
Ames II) or non-traditional approaches (e.g., fluctua-
tion assays, bioluminescence assays, SOS-response 
assays, or reporter gene assays). In addition, a number 
of bacterial mutagenicity assays based on DNA repair 
such as the SOS chromotest and the Salmonella SOS/ 
umu assays have been developed. The initial bacterial 
assays are generally followed up by a mammalian cell 
assay to detect DNA damage. Several reporter gene 
assays using human-derived cell lines exist. They 
are based on the activation of DNA repair genes with 
luminescence (e.g., Bluescreen) or fluorescence (Gree-
nscreen) detection[30,31]. Furthermore, also chromo-
somal damage can be evaluated in a higher throughput 
screening setting in mammalian cells by analyzing 
micronucleus formation using flow cytometry[32] or 
high content screening methods[33]. The performance 
of some models is presented in Table 2. 
Over recent years, computational toxicology has 
gained a lot of importance in drug discovery and re-
sulted in the development of several in silico struc-
ture-activity relationship (SAR) tools for the predic-
tion of toxicity[34,35]. The use of computational tools to 
identify potential genotoxicity based on the chemical 
structures is part of most mutagenicity screening 
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Figure 1. Examples of strategies used by pharmaceutical companies to select the most promising compounds. ($) Lundbeck[184],with 
permission from Elsevier. (%) UCB BioPharma SPRL. Blue, yellow and pink boxes refer to in silico, in vitro and in vivo approches, 
respectively. Abbreviations: BP: blood pressure; ECG: electrocardiogram; FIM: first-in-man; GLP: good laboratory practices; hERG: 
human ether-a-go-go related gene; HR: heart rate; IC50: half maximal inhibitory concentration; iPS: induced pluripotent stem cells; 
LVP: left ventricular pressure.  
(B) 
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Table 2. Performance of in silico, in vitro and in vivo approaches to predict different toxicity endpoints. Sensitivity and specificity 
data are reported. Values <50% are highlighted in red, 50% < values < 75 % are highlighted in yellow and those >75% appear in 





to predict in animal or human 
Sensitivity (%) Specificity (%) References 
In silico NA Hepatotoxicity 68 95 [179] 
Commercial softwares (DEREK, 
Toxtree, MC4PC, Leadscope MA) 
Ames test: public data 65.2–85.2 53.1–82.9 
[175] 
Ames test: Roche data 17.4–43.4 77.5–93.9 
NA QT in rabbits (diverse ion 
channel databases evaluated) 
60.0–91.4 27.6–80.8 [180] 
In vitro iPSCs (human) Arrhythmia 81 84 [176] 
hERG patch clamp (human) QT prolongation 82 75 [181] 
Ames (bacteria) Carcinogenicity 
in rodent 
60 74 [177] 
Micronucleus (hamster) Chromosomal damage, car-
cinogenicity 
94 85 [33] 
HepG2 (human) Hepatotoxicity 82 36 
[96] Primary hepatocytes (human) 83 46 




script in prep.) 
In vivo Rodent General toxicity 43 NA 
[51] 
Non-rodent 63 NA 
QT interval (dog) QT prolongation 83 86 [181] 
Cardiovascular telemetry (dog) Blood pressure 36 93 
[13] 
Heart rate 50 93 
Contractility 92 67 [182] 
Motor activity (Zebrafish) Seizure/convulsion 76 63 [178] 
Colonic motor activity (mouse) Diarrhea/constipation 90 75 [183] 
 
strategies before moving to testing, as it allows the 
quick evaluation of large numbers of compounds[36]. 
Commercial systems from various vendors (e.g., Lha-
sa Ltd., Leadscope Inc., MultiCASE Inc.) provide ge-
notoxicity databases for structural lookup and predic-
tive SAR systems. Often more than one method is 
available from each vendor, as the recent implementa-
tion of the ICH M7 (ICH M7, 2015) requires the use 
of two complementary methods, one rule-based and 
one statistics-based-method, for the assessment of 
potential genotoxic impurities (PGIs). The ICH M7 
guideline states that in the absence of an experimental 
result, two negative predictions from complementary 
computational methods together with an expert opi-
nion, is sufficient evidence for lack of mutagenic po-
tential of a PGI. As such, the use of in silico tools in 
the risk assessment of PGIs marks a milestone for the 
use of computational methods as it is the first example 
of such analyses being both acceptable and actually 
required for Regulatory submissions. 
2.3.2 Cardiotoxicity Safety Strategy 
Cardiotoxicity is one of the three major safety reasons 
for project failure or drug attrition in preclinical or 
clinical phases[6]. Between 1975 and 2007, 21% of 
drug withdrawals were due to cardiovascular safety 
issues[37]. During the last 10–15 years, a lot of empha-
sis has been put on QT prolongation and Torsades de 
Pointes (TdP) risk, in accordance with the ICH S7B 
and E14 guidelines. This regulatory strategy is being 
revisited through the novel paradigm of CiPA (Com-
prehensive in vitro Proarrhythmia Assay) focusing on 
in silico and in vitro approaches to screen new com-
pounds and better predict cardiac proarrhythmia risk 
in man[38–40]. However, QT prolongation and other 
arrhythmias are only one part of the iceberg, as they 
account for 23% and 4% of the cardiovascular issues, 
respectively[15,16]. Therefore, to increase the likelihood 
of success, an effective de-risking strategy should not 
solely cover proarrhythmia liability, but also integrate 
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hemodynamic and cardiac contractility assessment, 
and address both functional and structural aspects of 
cardiotoxicity. As exemplified by Figure 1, such str-
ategy usually consists of a combination of in silico, in 
vitro and in vivo models. In vitro assays aim at select-
ing compounds devoid of major liability on c ardiac 
ion channels involved in arrhythmia. Datasets gener-
ated in these ion channel assays can serve to build in 
silico models that will predict liability of new chemi-
cally-related molecules and help refine the SAR in a 
chemical series. In silico models simulating action 
potential effects of new drugs in human or animal car-
diac cells are also a growing field of development, as 
it is part of the CiPA paradigm[41]. In vivo cardiovas-
cular safety studies are mostly stand-alone single-dose 
studies conducted in rodents and non-rodents. The 
anesthetized guinea pig has emerged as an interesting 
model to screen compounds for both proarrhythmia 
risk and hemodynamic or contractility effects[42]. The 
conscious telemetered dog or non-human primate is 
used at later stages to confirm the absence of cardi-
ovascular risk of the candidate drug. Furthermore, card-
iovascular functional endpoints can be incorporated in 
repeat-dose toxicology studies in order to assess time 
course, duration, and reversibility of sub-chronic to 
chronic effects[43]. For this purpose, non-invasive (jac-
keted), ambulatory telemetry systems have been de-
veloped for use in dogs and primates.  
While pathophysiological and pharmacological me-
chanisms underlying functional cardiovascular effects 
such as QT prolongation, blood pressure changes, or 
inotropy are quite well understood, mechanisms ex-
plaining morphological damage to cardiomyocytes 
that could lead to cardiomyopathy or heart failure are 
less clear. Significant efforts are currently deployed to 
improve this understanding through the development 
of predictive cellular models combining various tech-
nologies. The use of stem cell-derived cardiomyocytes 
of human origin allows assessing, in a single assay, 
structural endpoints such as ATP depletion, calcium 
mobilization, mitochondrial membrane potential, and 
endoplasmic reticulum integrity[44], and functional end-
points like action or field potential, contractility, or be-
ating rate.  
The development, validation, and implementation 
of translational biomarkers providing further under-
standing of morphological and/or functional effects of 
cardiotoxicity have seen a sustained growth. One ex-
ample of more established molecular biomarkers are 
the cardiac troponins[45]. These have seen their applica-
tion gradually increasing in both preclinical and clini-
cal settings[46]. Another example is the current inves-
tigations into the use of microRNA (miRNA) bio-
markers (miR-208 and miR-1) as endpoints that fur-
ther support the interpretation of cardiotoxicity[47,48]. 
Due to their novelty, further studies addresses whether 
these can be considered as biomarkers of cardiac 
morphological and/or functional changes. The use 
of biomarkers is also moving towards an application 
in in vitro models (such as stem-cell derived cardi-
omyocytes) to improve their predictive value when 
translating findings into the clinical setting[49,50].   
In a study comparing the adverse effects of a series 
of new drugs in humans with those in animals, all ele-
ctrocardiographic changes in humans were also det-
ected in animals, and the Beagle dog appeared to be 
the best model[51]. Although the comparison of adv-
erse cardiovascular effects of drugs between humans 
and laboratory animals needs further investigations, 
there is a reasonable overall correlation[52]. However, 
some exceptions have emerged recently. As an exam-
ple, a number of anticancer drugs that target tyrosine 
kinases (e.g., trastuzumab and imatinib) have been 
associated with cardiac dysfunction in a small percen-
tage of patients but were not predicted in laboratory 
animals[53,54].  
Cardiovascular responses to injuries can be func-
tional, structural, or both. Changes in cardiac work us-
ually lead to structural morphological changes, which 
may ultimately lead to heart dysfunction. Morpholog-
ical evaluation includes the four chambers (ventricles 
and atria) of the heart and its different structural (va-
lves, large vessels) and histological components (myo-
cardium, endocardium, epicardium and pericardium). 
Blood vessels inside and outside the heart should be 
also considered. The conduction system is rarely well 
represented in routine histopathological sections and 
to allow a m ore specific evaluation, a collection of 
additional materials that include the sinoatrial node, 
the atrioventricular node, the bundle of His and spe-
cialized conduction fibers are needed. Samples are 
routinely stained using hematoxylin and eosin (H&E), 
but special stains may be of interest to characterize 
microscopic alterations. Immunohistochemistry, in situ 
hybridization and ultramicroscopy can also be useful 
to better identify morphological changes. Finally, ge-
netically modified animal models could be valuable 
tools for providing information on the pathogenesis of 
cardiovascular changes and the mechanism of action 
of various drugs[55].  
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2.3.3 Central Nervous System (CNS) Safety Strategy 
Twenty five percent of the CNS projects are closed 
due to CNS liabilities[6]. According to a recent sur-
vey[56], the most frequent CNS issues encountered 
preclinically are seizures, gait abnormalities, tremors, 
emesis/salivation and sedation while in phase I clini-
cal trials, emesis/nausea, fatigue, headache and dizzi-
ness are the most frequent ones. It is noteworthy that 
the last three effects are difficult to address preclini-
cally. In addition to those CNS issues, liability abuses 
(already widely regulated) as well as suicidal ideation 
often represent CNS risks appearing at later stages of 
the development or post marketing. From a regulatory 
point of view, CNS safety investigations are driven by 
regional (FDA: Guidance for Industry: Assessment of 
Abuse Potential of Drugs; EMA: Guideline for the 
Non-Clinical Investigation of the Dependence Poten-
tial of Medicinal Products) or global guidance (ICH 
S7A: Safety pharmacology studies for human phar-
maceuticals; ICH M3(R2): Guidance on non-clinical 
safety studies for the conduct of clinical trials and 
marketing authorization for pharmaceuticals) which 
mostly only address the in vivo safety and, this, at a 
quite late development stage (post candidate selection). 
These include standalone behavioral safety pharma-
cology studies and observation of clinical signs and 
brain histopathology in toxicity studies. Some spon-
sors opted for the inclusion of functional endpoints in 
repeat-toxicity studies, for scientific [New Biological 
Entities (NBEs)], long lasting effects, integration with 
toxicity and TK data…), ethical (National Center for 
Replacement, Refinement and Reduction of Animals 
in Research) and cost reasons[43]. However, this prac-
tice has shown some limitations (different laboratory 
conditions, dose levels, interference with the primary 
endpoints, HWF) that might reduce the quality of the 
signal[43]. 
At early stage, CNS toxicity assessment should fo-
cus on the physicochemical properties of the com-
pound (e.g., lipophilicity, protein binding) which will 
drive the propensity of the compound to cross the bl-
ood-brain barrier (BBB)[57]. Importance should also be 
given to the targeted disease as some pathophysiolog-
ical conditions are known to affect its permeabili-
ty[58,59]. With 75% of preclinical safety closures being 
off-target, in vitro pharmacological profiling takes on 
great importance in the reduction of the attrition 
rate by identifying undesired off-target activities at the 
early development stage[21]. 
Amongst the CNS’ adverse effects listed above, the 
industry mainly focuses on the investigation of sei-
zures which represent a high risk of drug failure at the 
late stage of development or withdrawal from the 
market. Screening cascades were developed including 
early in silico investigation, pharmacological profiling 
and high or medium throughput studies such as brain 
slice preparations or zebrafish models preliminary to 
the in vivo investigation in rodents[60]. Electroence-
phalograms along with video recording allow a further 
characterization of the seizure risk in rodents or larger 
species; the monkey being the species of choice with a 
high translatability potential to human[61]. The tre-
mendous progress made in this field over the last 
decade has led to better sensitivity, interpretation and 
reduction of cost and burden of the surgical implanta-
tion[62]. Nevertheless, the data should be interpreted 
with caution to ensure that the filter applied by all 
these tests is not too stringent and would potentially 
prevent some good compounds to reach patients[63]. 
Despite the paucity of the data comparing drugs-re-
lated adverse effects between animals and humans, 
animals are considered rather poor predictors of sub-
jective neurological effects. Laboratory animals are 
much better predictors of structural effects[52]. In a 
review on the concordance of the toxicities in humans 
and animals for 150 compounds, 49 out of 221 human 
toxicity observations were neurological in nature. Eig-
hteen of these compounds belonged to the neurologic 
therapeutic class and a significant percentage of these 
compounds did not progress to the market[51]. Over 
half of these adverse nervous system effects were 
judged to be related to the primary pharmacology.  
Structural neuropathology remains the ‘‘gold stan-
dard’’ for the assessment of experimental toxic neuro-
pathy even if special neurobehavioral assessment and 
electrophysiological tests help in the correlation of 
functional and morphological effects[64]. In conven-
tional toxicity studies, immersion fixation of the brain, 
spinal cord and nerves in formalin-based fixatives 
followed by paraffin wax embedding and H&E stain-
ing is the best approach as a routine screening method. 
Nevertheless, perfusion fixation should be preferred 
when special neuropathological assessment aims to 
characterize drug-induced changes found in the br-
ain[65]. Additional special histochemical staining is he-
lpful to better detect, characterize or quantify patho-
logical changes: cresyl violet (for neuronal features), 
Bielchowsky’s of Bodian’s stains (for axonal integrity), 
Luxol fast blue (for myelin integrity), amino cupric 
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silver (frozen sections required) or fluoro-Jade stains 
(for neuronal degeneration). Immunologic stains can be 
used to identify different cell populations. Glial fibril-
lary acidic protein is now classically used for the de-
tection of glial cells in laboratory animals while mar-
kers for neurons include synaptophysin, NeuN, neuro-
filament protein, neuron-specific enolase and micro-
tubule associated protein 2. Myelin associated glyco-
protein and myelin basic protein can be used to stain 
oligodendroglia[66]. For microglial cells, Iba1 and 
CD68 are among the most widely used microglia and 
macrophage markers[67]. On certain occasions, ultra-
structural assessment is needed to fully characterize 
pathological changes and typically requires dedicated 
investigations.   
A number of international regulatory guidance do-
cuments for neuropathology assessment in preclinical 
toxicity studies are available[68–70] and describe the 
zones to be included because of their specificities (e.g., 
high glucose consumption, blood vessels with fene-
strated endothelium). Finally, the development and 
implementation of CNS biomarkers is still in its initial 
stage. Several efforts have been made to develop flu-
id-based biomarkers and neuroimaging methodolo-
gies[71,72]. To this end, working groups such as those 
led by the Health and Environmental Sciences Insti-
tute are instrumental in assessing the utility of se-
lected biomarkers in a translational manner[73]. 
2.3.4 Hepatotoxicity Derisking Strategy 
Drug-Induced Liver Injury (DILI) is a major concern 
for the pharmaceutical industry as being one of the 
leading causes of drug withdrawals, non-approval, and 
regulatory actions. DILI is also a problem for care 
providers and patients because of its severity and 
sometimes fatal consequences. In addition, DILI rep-
resents a substantial part of ADRs, for which the total 
annual financial burden has been estimated to be as 
high as $177 billion in treatment costs in the United 
States[74]. DILI is generally divided into intrinsic (pre-
dictable) or idiosyncratic (unpredictable) categories. 
While intrinsic DILI results from drug-induced direct 
hepatotoxicity over the course of a few days, idiosyn-
cratic DILI occurs in a minority of susceptible indi-
viduals with a prolonged latency. The most common 
example of a drug causing predictable DILI is aceta-
minophen while examples of idiosyncratic DILI in-
clude those related to amoxicillin/clavulanate, nonste-
roidal anti-inflammatory drugs, and isoniazid[75]. With 
a low occurrence estimated to be within 1 in 10,000 to 
1 in 100,000[76], idiosyncratic DILI remains a major 
challenge with regard to its prediction and prevention.  
This is due to multiple factors including the nature of 
its reactions which lack a definitive correlation to the 
drug’s known pharmacological effects, the variation in 
temporal patterns with regard to drug exposure[77,78], 
and large dependence on individual susceptibility of 
affected patients.  
Pharmaceutical companies have taken various mea-
sures during preclinical phases of drug development 
that were intended to decrease the risk of DILI, by 
steering away from drug candidates that are perceived 
to be at “high risk”. Figure 1A illustrates the strategy 
set up by Lundbeck to discard hepatotoxic compounds. 
When clearly hepatotoxic agents are discovered from 
animal testing, they are usually rejected and not al-
lowed to enter into clinical phase[79]. As a consequ-
ence, there are limited data available for a systematic 
assessment of the predictive value of animal findings 
for DILI in humans. Most of the drugs that were found 
to cause severe DILI in humans did not cause signifi-
cant hepatotoxic effects in animals[79]. In contrast, 
there are examples of drugs that caused significant 
liver injury in animals[80] but are still considered very 
safe to the human liver. In a study by Olson et al.[51], 
55% of drugs known to be hepatotoxic to humans 
were correctly classified using standard animal models. 
However, many pharmaceutical companies still con-
tinue to rely on animal studies to predict DILI, 
which bears the risk of unnecessary termination of 
potentially safe and effective medications due to ad-
verse animal findings. 
DILI is challenging to predict in humans because 
many mechanisms may lead to hepatotoxicity as illu-
strated in Figure 2. For more details on the different 
mechanisms please refer to the publications by Lee[81] 
and Godoy et al.[82]. Among them, chemically reactive 
metabolites have been claimed to be often associated 
with hepatotoxicity because of their potential to irre-
versibly bind to and modify cellular macromole-
cules[83]. However, studies seeking to determine the 
predictive value of reactive metabolites and cova-
lent binding have shown conflicting results[84–86]. The 
direct link between the production of reactive metabo-
lites and occurrence of DILI is quite complex as it is 
the balance among bioactivation, detoxification, and 
defense mechanisms that determine whether a reactive 
metabolite elicits a toxic effect[87]. A recent study 
found that while in vitro covalent binding levels in 
human hepatocytes failed to predict DILI, multiplying  
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Figure 2. Overview of mechanisms of DILI. Figure extracted from Godoy et al.[82], with permission from Springer. (1) Detoxifica-
tion: conjugation with glutathione. (2) Altered calcium homeostasis. (3) Reactive metabolites may bind to transport pumps or actin around 
the bile canaliculi preventing bile export. (4) R eactive metabolites binding to mitochondrial proteins may reduce ATP formation, 
produce ROS, and open the MPTP causing apoptosis. (5) Immune stimulation via the hapten or prohapten mechanisms leading to 
either humoral (B cell) or cell-mediated (Tcell) reactions. (6) Immune activation (PI mechanism with parent drug). (7) TNF receptor 
sensitivity may be heightened increasing responsiveness to TNF, leading to apoptosis. For more details, please refer to Godoy et 
al.[82]. 
 
the covalent binding amount by the maximum daily 
dose was able to discriminate between drugs that were 
considered hepatotoxic and those that were not[84]. Al-
though additional studies are required to confirm these 
initial observations, this apparent relationship between 
the doses of medications and DILI may assist in our 
understanding of and potential escape from DILI dur-
ing drug development and patient usage. 
In vitro assays using cell cultures have been tested 
for prediction of DILI but their predictivity is varia-
ble[88–90]. A very serious hurdle is the lack of standar-
dization of these in vitro models, which certainly lim-
its our understanding of how to best use them and the 
need for validation for potential use in regulatory sub-
missions[91]. In addition, scientists may also question 
the relevance of measuring general cytotoxicity mark-
ers in comparison to mechanistic endpoints. For insta-
nce, different studies investigated whether improved 
sensitivity of DILI prediction can be obtained by com-
bining data provided by diverse assays assessing dif-
fering mechanisms. This approach has yielded very 
encouraging results[92], as have approaches that com-
bine in vitro assay data with physicochemical proper-
ties of drugs, and/or in vivo plasma exposure data[93,94]. 
If in vitro data are used for decision making, such 
models need to be validated very carefully because 
there is always the risk of terminating safe drugs for 
no valid reasons. Nevertheless, the scientific commu-
nity is developing more sophisticated human models 
including organ on a chip[95] and co-culture[96] models 
that have the potential to better detect hepatotoxicity 
in humans at the early stages of drug development. 
Moreover, the value of approaches such as in silico 
models[97], structural alert systems, and toxicogenom-
ics[98,99] for the prediction of DILI risk during drug 
development is still highly controversial. These ap-
proaches have indeed suffered from a lack of specific 
and sensitive biomarkers, scarcity of toxicological 
data, and lack of concrete unequivocal understanding 
of underlying mechanisms of most known hepatotoxic 
drugs[97]. 
In parallel to the ongoing request for new biomark-
ers and a better understanding of genetic and immu-
nologic factors accounting for predisposition to DILI, 
some drug makers have also implemented strategies in 
clinical development to use the information from early 
clinical trials to better predict potential risk of drugs 
for DILI. Indeed, it has become increasingly evident 
that milder forms of liver injury occurring in clinical 
trials, when evaluated properly, may significantly en-
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hance the ability to predict the drug’s potential to 
cause more severe liver injury in further development. 
Many drug makers have adopted strategies using Hy’s 
law [based on the use of well-established biomarkers 
such as alanine aminotransferase (ALT), aspartate am-
inotransferase (AST), bilirubin, and alkaline phospha-
tase], causality assessment of individual hepatic cases 
and adherence to strict hepatic discontinuation rules to 
prevent unnecessary early discontinuation of the study 
drug[100]. 
The use of translational molecular biomarkers in 
the context of hepatotoxicity strategies is character-
ized by the wide application of well-established mar-
kers such as ALT, AST, bilirubin and the deployment 
of novel biomarkers ranging from proteins, such as 
high-mobility group Box 1 (HMGB1) and colony sti-
mulating factor 1 receptor (CSF1R), to miRNAs such 
as miR122[101,102]. The former are widely used in both 
preclinical and clinical settings for risk assessment 
and management[103]. The latter, although showing the 
potential to be more precise and robust, still require 
further validation in the clinical setting before full 
implementation and investigations into their back- 
translational potential[103,104]. 
While microscopic evaluation on H&E stained for-
malin fixed paraffin embedded tissues can demon-
strate most of the hepatocellular and biliary alterations, 
additional special histochemical staining are usually 
required to better detect, characterize or quantify pa-
thological changes. Vacuoles and pigments are typi-
cally one of these examples and a set of staining can be 
applied to determine the nature of the content (e.g., per-
iodic acid-Schiff, Sudan’s dyes, or Oil-red-O). More 
elaborate techniques are sometimes required, such as 
immunohistochemistry (IHC) or electron microscopy 
(EM) to definitively demonstrate the nature of the 
material. For example, an immunohistochemical ap-
proach using lysosomal-associated membrane pro-
tein-2 or the demonstration of the characteristic ultra-
structural multilaminated whorl of material in lyso-
somes by EM can aid for the differentiation of phos-
pholipidosis from lipidosis. Pigments are a second ex-
ample, as most pigments present a brownish-greenish 
yellow appearance when stained with H&E and it is 
sometimes difficult to determine their nature (see Sec-
tion 3, second case study).  
2.3.5 Other Target Organ Safety Strategies  
Respiratory, renal and gastrointestinal systems are inv-
olved in only 3% to 9% of safety failures in preclinical 
or clinical phases[6]. Probably due to this low contri-
bution in drug attrition rate, pharmaceutical compa-
nies rarely establish routine de-risking safety strate-
gies for these target organ systems. Such strategies are 
applied on a case-by-case basis, when the primary 
target or the secondary pharmacology profile is asso-
ciated with potential liabilities for these systems.  
From a regulatory perspective, the respiratory sys-
tem is part of the safety pharmacology core battery 
that investigates the effects of the test substance on 
vital functions (ICH S7A guideline). As a minimum, 
respiratory rate and tidal volume should be measured, 
as clinical observations are not adequate to properly 
assess respiratory function. Stand-alone respiratory 
studies can be performed using techniques such as the 
whole-body or head-out plethysmography. Respiratory 
functional endpoints can also be integrated in general 
toxicology studies, in particular in non-rodents. The 
respiratory inductive plethysmography using jacketed 
external telemetry (chest bands) allows an accurate 
and non-invasive measurement of respiratory function. 
Additional parameters such as hemoglobin oxygen 
saturation or blood gases might also provide useful 
information.  
In contrast with respiratory function, renal and ga-
strointestinal (GI) functions are not considered as ‘vi-
tal’ and therefore, are not part of the safety pharma-
cology core battery. However, supplemental studies 
can be conducted to evaluate suspected adverse effects 
on these systems. GI side effects observed in the clinic 
are mainly nausea/vomiting and intestinal transit dis-
turbances (diarrhea or constipation). Although not 
life-threatening, such side effects can greatly impact 
the quality of life. GI function assessment should cov-
er GI motility, nausea and emesis liability, secretory 
function and absorption[105]. A variety of in vitro mod-
els allows studying the effects of substances on sm-
ooth muscle and enteric nervous system without the 
influence of external factors[106]. In vivo gastric emp-
tying and intestinal motility can be investigated in 
simple models such as the charcoal meal transit test in 
rodents. New promising technologies like wireless 
devices (SmartPill™, Bravo™ capsule) provide non- 
invasive GI endpoints such as changes in temperature, 
pH or pressure, but to this point can only be used in 
large animals[107,108]. Assessment of nausea and emesis 
liabilities requires in vivo models, as no in vitro tool is 
capable of reproducing such complex physiological 
events. Emesis evaluation can be conducted in dogs, 
ferrets, primates or shrews. It usually consists of sim-
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ple visual recordings of retching and vomiting epi-
sodes. More sophisticated techniques combining vid-
eo-monitoring and telemetric measurement of abdo-
minal pressure and electromyography can also be 
used[109,110]. 
Acute or chronic drug-induced kidney injury (DIKI) 
is mainly associated with small molecules and can 
consist of diverse pathological manifestations (inters-
titial nephritis, tubular cell toxicity, glomerulonephri-
tis, rhabdomyolysis,HWF)[111]. The mechanisms involved 
are poorly understood and histopathology remains the 
gold standard to detect DIKI. However, recent devel-
opments in the biomarkers field have emerged. Seven 
urinary biomarkers (kidney injury molecule-1, cluste-
rin, albumin, total protein, β2-microglobulin, cystatin 
C and trefoil factor 3) have been qualified by the FDA 
for use in GLP rat studies[112,113]. Their appearance or 
excretion in urine offers the promise of greater sensi-
tivity and utility to detect early stages of DIKI, before 
histopathology changes occur. In addition to these bio-
markers, renal function is addressed through various 
in vitro and in vivo models. In vitro experiments can be 
conducted on isolated perfused kidney preparations, 
renal slices or different kidney cell lines[114]. In vivo 
assessment of renal function should cover glomerular 
function (measurement of glomerular filtration rate), 
tubular function (through plasma or urine markers 
such as creatinine, electrolytes), and hemodynamic 
function (renal blood flow, renal vascular resistance).  
3. Mechanistic Investigations: Case Studies  
Understanding the mechanisms of toxicity and as-
sessing the associated risks can represent a key chal-
lenge when it comes to provide timely go/no go deci-
sions that may result in the removal of a compound. 
Here, two examples of the successful integration of 
investigative toxicology experiments to support drug 
discovery process are provided. The first case study 
involves ticagrelor, an inhibitor of platelet aggregation, 
which is used together with aspirin to prevent athe-
rothrombotic events as treatment of patients with 
acute coronary syndromes. Its antiplatelet and clinical 
activity is mainly mediated through its potent and re-
versible inhibition of the platelet P2Y12 receptor
[115,116]. 
Compared to clopidogrel (another contemporary anti-
platelet agent), ticagrelor significantly reduces the risk 
of heart attacks. Moreover, data collected during tica-
grelor clinical development showed that treatment 
with ticagrelor as compared with clopidogrel also sig-
nificantly reduced the rate of all-cause mortality[117]. 
Dyspnea and ventricular pauses were observed in some 
patients treated with ticagrelor[117–119]. These observa-
tions suggested a l ikely additional mechanism of ac-
tion for ticagrelor, i.e., adenosine mediation[120–122]. In  
the in vitro and ex vivo studies performed by Arms-
trong et al.[123], the authors further characterized tica-
grelor pharmacology with respect to adenosine media-
tion. They examined ticagrelor effect on specific ade-
nosine transporters using recombinant cells, perfor-
med receptor ligand binding and functional assays and 
assessed adenosine and ticagrelor effects in ex vivo 
guinea pig and rat C fiber preparations[123]. Thanks to 
these investigations, the authors showed that ticagrelor 
inhibited cellular adenosine uptake selectively via 
equilibrative nucleoside transporter (ENT) 1 inhibition 
at concentrations of clinical relevance. In addition, 
ticagrelor displayed low binding affinity and function-
al inhibition of adenosine receptors suggesting that a 
direct effect of ticagrelor on adenosine receptors was 
unlikely to be of clinical relevance. Hence, ENT1 in-
hibition by ticagrelor can potentially contribute to the 
overall clinical benefit of ticagrelor compared to clo-
pidogrel (that had no effects on ENT1 transfected 
cells). Overall, this provides a comprehensive set of in 
vitro/ex vivo data that contributes to understand tica-
grelor adenosine mediated mechanism of action, 
which help to explain the clinical picture of ticagrelor 
treated ACS patients.    
The second case study describes an antiepileptic 
synaptic vesicle 2a ligand drug candidate that, when 
tested in 4-week rat and dog oral toxicity studies, eli-
cited different liver findings depending on t he spe-
cies[124]. Indeed, as illustrated in Figure 3, dark pig-
ment deposits were detected in the liver of high dosed 
(200 mg/kg/day) dogs while no adverse effects were 
observed in the rats at any dose tested (up to 1000 
mg/kg/day). Of note, rats were exposed to higher par-
ent drug levels compared to dogs [toxicokinetic (TK) 
data]. The morphology of the liver deposits, accompa-
nied by increases in the plasma liver enzymes and a 
slight elevation in bilirubin, were suggestive of hepat-
ic porphyria with accumulation of porphyrin and po-
tential neurovisceral complications[125]. By conducting 
a thorough TK analysis and performing in vitro meta-
bolism assays in primary hepatocytes from different 
species, Nicolas et al.[124] showed that the dog was 
more prone than the rat to oxidize the drug candidate 
into a porphyrogenic metabolite. Ex vivo tissue mea-
surements did help elucidate the cascade of events  
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Figure 3. Liver section from a 200 mg/kg/day treated dog s tained with hematoxylin and eosin ($) and under polarized light (%). 
Brown pigments were observed in bile canaliculi (star), and in the cytoplasm of Kupffer cells (arrow) and hepatocytes (arrowhead) 
($). Porphyrin pigments are characterized by red birefringent properties (white star and arrowhead) under polarized light and can be 
differentiated from lipofuscin deposits (white arrow) (%). Original magnification: ×200. 
 
underlying the porphyria observed in dog. Hence, the 
pigment in the liver of treated dogs was the result of 
protoporphyrin IX accumulation. The latter was linked 
to a decrease of hepatic ferrochelatase activity, as well 
as combined induction, and inactivation of cytoch-
rome P450 CYP2B11. The causative agent for the 
disrupted heme biosynthetic cascade in treated dogs 
was identified by mass spectrometry as an N alkyl-
protoporphyrin adduct formed by a reactive metabolite. 
Decisively, the authors assessed the translatability of 
these findings in humans and demonstrated that this 
particular metabolite was not produced in rats or in 
humans. Altogether, these findings enabled Nicolas et 
al.[124] to conclude that the protoporphyria elicited by 
the drug candidate in dog livers was not of clinical 
relevance. Therefore, the drug candidate should nei-
ther induce protoporphyria nor activate quiescent in-
herent porphyria in humans. This work also highlights 
the species variability that can be observed with drug 
induced porphyria and the consecutive challenge of 
extrapolating animal toxicity data to human. For this 
reason, in vitro approaches have also been described 
to elucidate porphyria species variability[126,127]. 
In conclusion, these two case studies[123,124] per-
fectly illustrate how investigating the mechanisms of 
action can help to progress or stop a compound, even 
at a late stage of drug development. Moreover, as ex-
emplified in both reports, successfully addressing key 
safety issues requires most often a combination of in 
vitro, ex vivo and in vivo approaches, at the time of an 
increasing debate regarding the clinical outcome pre-
diction by animal toxicology testing[128–130]. 
4. New Trends in Investigative Safety 
4.1 Computational Models Impacting Investigative 
Safety  
The high attrition rates due to safety issues have been a 
strong driver during the past decade in developing and 
applying computational models for toxicological 
endpoints. Models, or other computational tools, can be 
applied in most stages during drug discovery and de-
velopment, and should ideally be aligned to the expe-
rimental target organ strategies to support and com-
plement these in an integrated fashion. Very early on, 
during the safety evaluation of the target, bioinformatic 
methods such as pathway analysis[131] are largely em-
ployed with chemo-informatic methods, becoming 
more applicable in the lead identification stage and 
onwards. The methods used in various stages of drug 
discovery depend on factors such as the abundance of 
available data, quality of those data, and the intended 
usage of the output. To a high degree, this correlates 
with the complexity and accuracy of the data generated 
in projects at various stages. High or medium through-
hput in vitro screening data are often used for the gen-
eration of machine learning models, such as quantita-
tive structure-activity relationship (QSAR) models. 
The datasets are often rather large (thousands to tens of 
thousands of compounds) and can vary in origin from 
proprietary, public or a mixture of both. These models 
are usually comprised of diverse chemical compounds 
and are commonly referred to as “global” models. Ion 
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channels, such as hERG and Nav1.5 or some of the 
targets mentioned by Bowes et al.[21], are common to 
model using such methods, with the aim of selecting 
compounds for experimental screening or to prioritize 
which chemical series to pursue. Predicting potential 
off-target effects via the compounds’ interaction(s) 
with other proteins can be done either on a n ad hoc 
problem solving basis or as part of profiling of com-
pounds/series. This is frequently done by looking at 
chemical similarity and drawing conclusions based on 
the targets that similar compounds interact with[132–136]. 
It is desirable in this context to also relate in vitro to in 
vivo data. Some work has been published relating the 
experimental interaction patterns of in vitro results to in 
vivo toxicology studies by looking at biological simi-
larities[63]. “Structural alerts”, chemical substructures 
that have been shown to be mechanistically relevant to 
a specific toxicology endpoint, are often used for 
endpoints of chemical toxicity. These include mutage-
nicity and skin sensitization but they may also be used 
in situations where the data sets are not of high enough 
quality or large enough to support quantitative model-
ing. Garcia-Serna et al.[137] recently published a m e-
thodology to link structural alerts and secondary target 
effects to human side effects. The comparison of 
chemical analogs, or “read across”, is also a common 
practice for risk assessment of compounds for chemical 
toxicity endpoints. This entails drawing conclusions 
for untested compounds based on the structural com-
parison to similar compounds with associated experi-
mental data. As mentioned previously, the use of 
computational tools is required in the context of PGIs 
and regulatory submissions through the application of 
the ICH M7 guidelines. Many of the methods men-
tioned above have been around for a number of years 
and are often well embedded into the preclinical dis-
covery processes. The future of computational work in 
this field lies in the more complex relationships relating 
high content data (such as phenotypic and genotypic 
information) to toxicological outcomes. This will infer 
high demands on k nowledge management and tho-
rough understanding of the underlying mechanisms at 
hand, as it is far from trivial to connect molecular 
events to clinical events. It is however clear that there is 
room for improvement in this field and that computa-
tional tools are maturing and becoming embedded and 
aligned with the experimental target organ strategies.  
4.2 Mitochondrial Toxicity Assessment  
Organ toxicity strategies can be complemented by 
investigating a common underlying mechanism of 
those toxicities. For instance, mitochondrial toxicity 
has been reported to be one of the main primary caus-
es of various organ toxicities induced by xenobio-
tics[138–140]. These include drugs that induce hepatoto-
xicity[141,142], cardiotoxicity[143–144], nephrotoxicity[145] 
and neurotoxicity[146]. Drugs were also reported to 
cause multiple organ toxicities due to mitochondrial 
dysfunction. For instance, the adverse effects asso-
ciated with fialuridine, i.e., nausea, vomiting and pai-
nful paraesthesia with subsequent hepatic failure; pan-
creatitis, neuropathy, myopathy and lactic acidosis, are 
probably due to multisystem mitochondrial toxici-
ty[147]. In addition, co-administration of drugs can in-
crease the risk of drug-induced mitochondrial toxicity 
and the latter can also be associated with genetic pre-
dispositions[148]. Drugs can act in many distinct ways 
on the mitochondria. Some mitochondrial toxic com-
pounds, such as rotenone (pesticide inhibiting com-
plex I), act directly on the electron transport chain 
(ETC) and oxidative phosphorylation (OXPHOS). 
Other compounds may interact in an indirect way, for 
instance by reducing substrates needed for the ETC or 
damaging mitochondrial DNA (mtDNA)[139]. As an 
example, sodium valproate, an antiepileptic drug, in-
directly affects mitochondrial function by inducing 
carnitine deficiency, leading to a depression of intra- 
mitochondrial fatty acid oxidation, and consequently 
the inhibition of OXPHOS[149]. Some physicochemical 
properties have also been linked to mitochondrial tox-
icity. For instance, uncouplers of OXPHOS a re cha-
racterized as being hydrophobic weak acids (i.e., ph-
enols or amides) with a pKa of 5–7[139]. Recently, Ne-
lms et al.[150], developed an in silico profiler for mito-
chondrial toxicity based on structural similarity and 
molecular mechanism of mitochondrial toxicity. A 
high-throughput screening platform was also devel-
oped using isolated mouse liver mitochondria in order 
to detect global mitochondrial membrane permeabili-
zation (swelling), inner membrane permeabilization 
(transmembrane potential), outer membrane permea-
bilization (cytochrome c r elease), and alteration of 
mitochondrial respiration driven by succinate or ma-
late/glutamate[142]. Around 90% of oxygen consump-
tion by mammals occurs in the mitochondria with the 
ultimate objective of synthesizing ATP, oxygen con-
sumption can be used as an indirect readout of mito-
chondrial function[140,151]. A kinetic readout for cell 
energy metabolism applicable for screening purposes 
can be assessed with the extracellular flux (XF) ana-
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lyzers (Seahorse Inc.). XF analyzers concurrently mea-
sure oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR), indirect measures of OX-
PHOS and glycolysis, respectively[152,153]. In addition, 
specific parameters of mitochondrial function can be 
deduced through the addition of known mitochondrial 
stressors[149]. For example, the consecutive addition of 
oligomycin, FCCP, and a mixture of antimycin and 
rotenone after exposure to the compound will provide 
the effect of the compound on the OCR associated 
with ATP production, maximal respiratory capacity, 
proton leak and spare respiratory capacity[154]. Finally, 
mitochondrial toxicity should be assessed throughout 
the development of new chemical entities and the im-
plementation of biomarkers in pre-clinical and clinical 
studies is important. Reported side effects of drug in-
duced mitochondrial toxicities can help us to de-
fine biomarkers. For instance, hyperlactic acidemia, 
lipid accumulation (microsteatosis), hypoglycemia, 
hypoxemia and heat production are observed with 
ETC and substrate inhibitors[139].  
4.3 Impact of Technologies  
The pharmaceutical industry is under massive pressure 
from economical, regulatory, public and R&D point of 
views. There is a crucial need to implement innovative 
approaches and technologies as failure to innovate in 
drug development will render the “big pharma” model 
unsustainable[155]. The use of groundbreaking tech-
nologies should not only reduce the attrition rate due 
to efficacy and safety reasons, but also, avoid the huge 
cost associated to the development of well advanced 
drug candidates[155]. Different examples are provided 
in the following paragraphs to illustrate how the use of 
innovative technologies may greatly impact drug de-
velopment. Although the technologies/approaches des-
cribed in the next sections carry many advantages, 
there are also some limitations associated as with any 
technology (not described in this manuscript). Finally, 
to implement such technologies in the pharmaceutical 
industry, it is important to demonstrate that they have 
some added value compared to the traditional methods 
currently used in the drug development paradigm. 
In the field of Alzheimer’s disease, the use of posi-
tron emission tomography ligands, volumetric mag-
netic resonance imaging and fluid biomarkers has al-
lowed to better characterize the different steps of dis-
ease progression at molecular, functional, and struc-
tural levels. Nevertheless, the development of reliable 
markers to quantitatively assess cognitive domains 
that are subtly changed before memory is an urgent 
need since it is important to detect subjects at risk as 
early as possible. Leurent and Ehlers[156] provided a 
new concept on how emerging mobile, computer, and 
device-based cognitive tools are converting classically 
noisy, non-objective, data-poor clinical endpoints as-
sociated with CNS disease assessment into a r icher, 
scalable, and objective set of measurements. In sum-
mary, the prospect for transformative efficiency and 
accuracy in testing novel therapeutics in neurodege-
nerative disease may rest in the devices we each day 
carry in our pockets[156]. 
Compound PK, PD and transport data in the differ-
ent tissues collected from animal studies are crucial 
during the early stages of drug development. Traditio-
nally, the abundance and distribution of drugs have 
been assessed by well-validated methodologies in-
cluding, for instance tissue homogenization with liq-
uid chromatography/mass spectrometry (LC/MS) 
analysis and/or whole-body autoradiography (WBA). 
Unfortunately, LC/MS, despite its remarkable sensi-
tivity, does not provide information on spatial distri-
bution and WBA does not make any distinction be-
tween parent compound and metabolites. In contrast, 
mass spectrometry imaging (MSI) can discriminate 
drug and its metabolites and endogenous compounds, 
while simultaneously reporting their distribution[157]. 
MSI data are influencing drug development and are 
currently used in investigational studies in areas such 
as compound toxicity[157]. Hence, MSI data generated 
from animal studies results may soon be used to sup-
port new drug regulatory applications, although clini-
cal trial MSI data will need more time for the valida-
tion and incorporation into submissions.  
Finally, the use of label-free technologies applied to 
cell biology and drug discovery is receiving more and 
more attention[158]. Platforms based on acoustic re-
sonance, electrical impedance, microcantilevers, na-
nowires, and differential calorimetry are beginning to 
appear, with commercially available products for 
post-high-throughput screening hit confirmation and 
mode-of-action studies[159]. The advantages of label- 
free detection include a simple homogeneous assay for-
mat, non-destructive methodology, reduced interfe-
rence with normal cell function, kinetic measurement 
(Figure 4), and limited time for assay development. As 
an example, real-time cell analyzer (RTCA), a la bel- 
free technology based on impedance measurement, can 
be used to generate information on cell proliferation, 
migration, viability, and receptor-mediated signaling,  
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Figure 4. Example of label-free data (Real-Time Cell Analyzer). Figure extracted from Atienzar et al.[96], with permission from El-
sevier. HepG2 cells were exposed to DMSO and/or troglitazone. Cells were exposed to 0 (0. 5% DMSO, red curve), 12.5 Cmax 
(green curve), 25 Cmax (purple curve), 50 Cmax (dark blue curve) and 100 Cmax (light blue curve) μM. Cmax refers to the maximal 
concentration of a given compound in human blood. Troglitazone is known to be hepatotoxic in human and the drug was withdrawn 
from the market. Cmax value (troglitazone) = 6.39 µM. Cell indexes were normalized with the last time point before compound addi-




associated with very specific and well-defined chan-
ges in cell morphology and adhesion[158,160].  
4.4 Impact of Cellular Models 
For the development of new chemical entities, the 
current model in toxicology is mainly based on in vivo 
testing using rodent and non-rodent species to support 
studies in human. Unfortunately, animal studies are 
not optimal for predicting human toxicity[51], in part 
due to species-specific differences in ADME between 
human and animal models, as well as the use of hea-
lthy animals with limited genetic diversity for prec-
linical toxicology studies[96]. Consequently, it is of 
primary importance to have access to relevant in vitro 
models including but not limited to rat, dog and hu-
man cellular models. It has been estimated that up 
to 70% of assays developed for drug screening and 
discovery are cell-based assays[161]. However, it is 
important to show that the new cellular models are 
carefully validated with superior predictive values 
compared to traditional cellular models. 
Organ-on-a-chip, which is becoming more and more 
popular, is a cell culture model with microfluidic cha-
nnels[162] with the possibility to simulate activities and 
physiological responses of an entire organ. Different 
“organ-on-a-chip” devices have already been created. 
One of the first ones is the “lung-on-a-chip” model 
made by the Wyss Institute at Harvard (US)[163]. The 
following step for this approach is to make connec-
tions of many organ on-a-chip devices to create a 
“body-on-a-chip”. This configuration could possibly 
allow researchers to investigate the effects of sub-
stances not only on the individual organs but to repli-
cate the interactions between each component, pro-
viding a more comprehensive analysis which could 
ultimately revolutionize how drugs are developed[162]. 
To overcome the deficiencies of existing in vitro 
liver models (e.g., HepG2, primary hepatocytes), 
Khetani and Bhatia[164] developed a co-culture model 
constituted of hepatocytes and mouse fibroblasts. 
Primary human or rat hepatocytes in the co-culture 
models are viable, have functioning bile canaliculi 
network and sustained expression of metabolic en-
zymes, transporters and liver specific proteins for at 
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least four weeks[164]. Many investigations have al-
ready been performed to carefully study metabolic 
capacities as well as prediction to detect human hepa-
totoxic drugs[96,165,166]. In a recent study, a s et of 51 
drugs including 40 hepatotoxic drugs and 11 non-hep-
atotoxic drugs was investigated in the in dog co-cu-
lture model[96]. Overall, the aforementioned studies 
indicate that the co-culture models may better mimic 
in vivo situations as they seem to represent relevant 
tools to perform chronic hepatotoxicity and metabol-
ism studies. Sensitivity and specificity data with 
co-culture models are presented in Table 2.  
Finally, a recent technological development allows 
obtaining human induced pluripotent stem cells (hi-
PSCs) from the skin, which can be used to generate 
patient-specific cardiomyocytes (CMs) under in vitro 
conditions. This means that each hiPSC produced from 
patient fibroblasts carries the relevant genetic infor-
mation. hiPSCs have been used to recapitulate disease 
phenotypes of genetic cardiac diseases such as long QT 
(LQT), familial hypertrophic cardiomyopathy (HCM), 
and familial dilated cardiomyopathy (DCM)[167–169]. 
Patients suffering from LQT, HCM, and DCM syn-
dromes are particularly sensitive to cardiotropic drugs 
and are vulnerable to fatal arrhythmias[170]. Recently, 
Liang et al.[171] characterized a library of hiPSC-CMs 
derived from patients with LQT, HCM, and DCM and 
screened them against a panel of drugs known to af-
fect cardiac ion channels. Drug-induced cardiotoxicity 
profiles were recapitulated for healthy subjects, LQT, 
HCM, and DCM patients at the single cell level for 
the first time. The data clearly reveal that healthy and 
diseased individuals display different susceptibilities 
to cardiotoxic drugs[171]. hiPSC-CMs can detect drug- 
induced cardiac toxicity more accurately than the 
classical preclinical assays mandated by regulatory 
authorities. In summary, these investigations illustrate 
well the concept of personalized medicine through in 
vitro assays which allow assessing the genetic suscep-
tibilities of distinct individuals to better predict clini-
cal outcome[171]. This is certainly essential as the ma-
jority of cardiotoxic drugs have a low incidence of 
harmful effects for the general population but are toxic 
to specific patient populations with determined genetic 
traits. Finally, Figure 5 illustrates how iPSC could be 
used for drug and chemical safety assessment.  
 
 
Figure 5. Potential use of iPSC for drug discovery and chemical safety assessment. Figure extracted from Jennings[185], with permis-
sion from Elsevier. Abbreviations: iPSC: induced pluripotent stem cell; PBPK: Physiologically Based Pharmacokinetic.  
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4.5 In Vitro Toxicology Assessment to Support 
%Lologics  
For biologics, the main safety liabilities are related to 
the target itself and often reflect exaggerated pharma-
cological action[172]. The use of in vitro assays is 
mainly, but not exclusively, focused on the following 
areas at different stages of drug development. Before 
candidate selection, major biological target-related 
safety liabilities can be identified from known litera-
ture about the target, competitor drug liabilities and/or 
early experimental work. It may be of benefit to com-
pare various candidates or even formats for the identi-
fied liability in an appropriate human in vitro system. 
As an example, FcyR-mediated cross-linking by an 
antibody targeting a cell-surface molecule may trigger 
an unwanted immunological effect such as antibo-
dy-mediated cellular cytotoxicity, unwanted cytokine 
release or platelet activation. In such cases, a head-to- 
head comparison of various formats (different Fc parts 
silenced for specific interactions or e.g., Fab frag-
ments lacking the Fc parts) is useful to support candi-
date selection in a complex weighting with other pa-
rameters assessed to drive optimal selection. 
During preclinical development in vivo, safety 
findings from preclinical in vivo assessments in rele-
vant species often raise the question about translata-
bility to man. In such cases, in vitro toxicological as-
sessments in human in simple (e.g., cell line) to more 
complex settings (e.g., organoid culture) may help to 
understand this aspect. An in-depth understanding of 
the biology and function of the target across the spe-
cies is an important prerequisite. An experimental ap-
proach often chosen is to try to recapitulate the in vivo 
findings in the toxicological species in vitro system to 
increase the confidence that potential effects in human 
can be predicted. Such assays may often have an im-
pact on the minimum anticipated biological effect lev-
el approaches to determine the starting dose in man 
when the safety effect is directly related to the mode 
of action. Consequently, this may act both as sensitive 
pharmacodynamics and safety marker[173]. Another bio-
logics-specific aspect is the generation of anti-drug 
antibodies that may cause through the formation of 
immune complexes various inflammatory responses 
including glomerulonephritis, vasculitis, thrombosis 
or even anaphylaxis, that are in rare cases found in 
man[174]. However, the frequency of anti-drug antibo-
dy responses observed preclinically is usually not 
translatable to man and pathogenic immune complex-
es may not form at the much lower human doses. The 
major goal of in vitro toxicology is in this case to ex-
clude the direct functional target involvement in the 
preclinical findings. During clinical development, 
safety liabilities may become obvious which were not 
observed in the non-clinical species. This can have a 
variety of reasons: (i) the non-clinical toxicology spe-
cies may not adequately predict all safety endpoints in 
man, due to limited similarity in expression patterns, 
functions, intercalating pathways, additional target 
functions in a species or sensitivity of the target ac-
tion-related events, and (ii) the limited number of an-
imals assessed in vivo does not allow to pick up rare 
safety events in man which are only discovered when 
large and more heterogeneous populations enter clini-
cal trials as of Phase 3 and post-marketing. An in vitro 
toxicological species-comparative investment can 
highly increase the understanding of adverse events in 
the clinic and in the case of events in only a subpopu-
lation of humans help to identify patients at risk (e.g., 
such bearing a specific allelic variant of the target). 
5. Predictivity of the Models in the Different 
Target Organ Strategies 
Over the last few years, data have been generated to 
assess the value of non-clinical tests to predict the 
potential drug effects in humans (but also in ani-
mals) by defining the parameters such as sensitivity 
and specificity of any given models (Table 2). The 
sensitivity of a model reflects the proportion of drugs 
whose effects in man are correctly identified by the 
model. A high sensitivity reflects a low rate of false 
negatives. The specificity of a model defines the pro-
portion of drugs without an effect in humans that is 
correctly identified by the model. A high specificity 
reflects a low rate of false positives.  
It is important to identify and eliminate, wherever 
possible, safety hazards during the early drug discovery 
phases, e.g., lead optimization[21,40]. Therefore, assays 
used during this phase should be highly sensitive, with 
great specificity. Table 2 gives examples of the per-
formance of multiple approaches to predict toxicity 
effects in human (or in animals). Commercial in silico 
packages such as DEREK, Toxtree, MC4PC, and 
Leadscope MA performed relatively well to predict 
Ames data for compounds in the public domain and 
displayed reasonable specificity (77.5%–93.9%) but 
low sensitivity (17.4%–43.4%) with Roche chemical 
space[175]. This could be related to the fact that the  
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Roche chemical space is not well covered by the public 
chemical space which is not surprising. The hERG 
assay, which showed high sensitivity (82%) with 75% 
specificity is generally positioned during the early 
discovery phases despite the non-negligible rate (25%) 
of false positive (Table 2). Other in vitro assays (e.g., 
iPSCs) have better predictivity compared to the hERG 
assay but are not as thoroughly validated compared to 
the potassium channel assay[176]. The in vivo QTc assay 
in non-rodent species, which has overall good predic-
tivity (ca 85%) is well positioned during the candidate 
drug selection phase assuming an adequate exposure 
range is tested (i.e., at least 30-fold)[129]. With regard to 
genotoxicity, the Ames assay which is part of the reg-
ulatory genotoxicity package to enter clinical testing 
displays sensitivity of 60% (i.e., 40% chance for false 
negative results) and specificity of 74% (i.e., 26% 
chance of generating false positive results) (Table 2). 
Based on the publication of Tilmant et al.[33], the Chi-
nese hamster ovary micronucleus test performs better 
(Table 2) but it is worth mentioning that other publica-
tions have reported a much lower specificity in mam-
malian assays[177]. Finally, measuring motor activity in 
zebrafish allows to relatively well predict seizure and 
convulsions with sensitivity and specificity close to 
70%[178]. Many other models and assays are presented 
in Table 2 but will not be discussed further in this sec-
tion. To conclude, understanding the predictive value 
of nonclinical safety testing for humans enables to 
optimally align assays to address the key objectives of 
the drug discovery process, i.e., hazard identification 
and elimination, risk assessment, management and 
mitigation.  
6. Conclusion and Final Remarks 
Understanding and reducing attrition rate remains a 
key challenge in drug development. Preclinical and 
clinical safety issues still represent about 40% of drug 
discontinuation, of which cardiac and liver toxicities 
are the leading reasons. One would hope that increas-
ing the extent of safety testing early during the drug 
discovery phases should enable to identify and elimi-
nate safety hazards, therefore leading to the develop-
ment of safer medicines with fewer and less severe 
ADRs and acceptable risk/benefit ratios in a given 
disease and patient population setting. Reducing attri-
tion rate can be achieved by various means, starting by 
a comprehensive evaluation of the potential safety  
issues associated to the primary target as well as to 
undesirable secondary (off targets) pharmacological 
activities. To address these risks, a risk mitigation plan  
should be built at very early development stages, us-
ing a panel of in silico, in vitro and in vivo models. 
While most biopharmaceutical companies have de-
veloped robust safety strategies to de-risk genotoxicity 
and cardiotoxicity issues, partly driven by regulatory 
requirements, safety issues affecting other organs or 
systems, such as the liver, kidney, the central nervous, 
or gastro-intestinal systems, are less commonly ad-
dressed during early drug discovery. Some early dis-
covery strategies can be applied to these target organ 
systems, including the use of novel biomarkers that 
can be easily integrated in both preclinical and clinical 
studies. The present manuscript highlights the impor-
tance and impact of investigative experiments to un-
derstand the mechanisms underlying toxicities and 
their human relevance that arise either in non-clinical 
chronic toxicology studies or clinical trials, thus 
enabling to form an integrated risk assessment, and to 
develop risk management and mitigation plans. Novel 
trends in investigative safety have been also reviewed, 
such as computational modeling, mitochondrial toxic-
ity assessment, and imaging technologies that may bec-
ome an integral part of drug safety testing. Assessing 
and integrating novel technologies and the latest 
scientific advancements as well as shaping and im-
plementing emerging and future regulatory require-
ments may enable to further enhance our confidence 
in designing, and selecting drug candidates that have 
an increase likelihood of becoming successful medi-
cines benefiting patients throughout the world. 
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Appendix 1: List of Abbreviations 
Abbreviation What it stands for 
ADME absorption, distribution, metabolism and elimination 
ADRs adverse drug reactions 
ALP alkaline phosphatase 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
BBB blood-brain-barrier 
CiPA Comprehensive in vitro Proarrhythmia Assay 
CMs cardiomyocytes 
CNS Central Nervous System 
CSF1R colony stimulating factor 1 receptor 
DCM dilated cardiomyopathy 
DIKI drug-induced kidney injury 
DILI drug-induced Liver injury 
ECAR extracellular acidification rate 
EMA European Medicines Agency 
ETC electron transport chain 
EM electron microscopy 
ENT equilibrative nucleoside transporter 
FDI Food and Drug Administration 
GI gastrointestinal 
HCM hypertrophic cardiomyopathy 
H&E hematoxylin and eosin 
hERG Human Ether-a-go-go-Related Gene 
hiPSCs human induced pluripotent stem cells 
HMGB1 high-mobility group Box 1 
ICH International Conference on Harmonization 
KO knock-out 
LC/MS liquid chromatography/mass spectrometry 
LQT Long QT 
miR microRNA 
mtDNA mitochondrial DNA 
MSI mass spectrometry imaging 
NBEs New Biological Entities 
OCR oxygen consumption rate 
OXPHOS oxidative phosphorylation 
PGIs Potential Genotoxic Impurities 
PD Pharmacodynamics 
PK Pharmacokinetics 
QT Duration of the QT interval of the electrocardiogram 
RTCA Real Time Cell Analyser 
SAR Structure Activity Relationship 
TdP Torsades de Pointes 
TSE Target Safety Evaluation 
TK toxicokinetics 
WBA whole-body autoradiography 
XF extracellular flux 
5HT2B 5-Hydroxytryptamine receptor 2B 
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